AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14656614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 10513866 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MP) 125 mg intravenously
Number of subjects: 20
Study 10513866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10513866 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MP)
Number of subjects: 20
Study 7500368 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy for Couples (EFT)
Number of subjects: 49
Study 7500368 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 49
Study 7500368 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibited sexual desire (ISD) couples
Number of subjects: 49
Study 1742400 — intervention group
Group type: EXPERIMENTAL
Intervention: r-IFN (3 MU subcutaneously three times a week for 24 weeks)
Number of subjects: 30
Study 1742400 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 30
Study 1742400 — intervention group
Group type: EXPERIMENTAL
Intervention: r-IFN
Number of subjects: 30
Study 7179188 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous irradiated tumour cells and BCG
Number of subjects: 0
Study 7179188 — intervention group
Group type: COMPARATOR
Intervention: Single preoperative injection of BCG
Number of subjects: 0
Study 31594253 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 352
Study 28922784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 19,541), goal of reducing total fat intake and increasing intake of vegetables, fruits, and grains.
Number of subjects: 48235
Study 28922784 — intervention group
Group type: COMPARATOR
Intervention: Usual diet comparison group (n = 29,294).
Number of subjects: 48235
Study 28922784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention among women with BMI ≥ 25 kg/m2.
Number of subjects: 48235
Study 28922784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention among women with BMI < 25 kg/m2.
Number of subjects: 48235
Study 26189647 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head cooling (SHC)
Number of subjects: 29
Study 26189647 — intervention group
Group type: COMPARATOR
Intervention: Whole-body cooling (WBC)
Number of subjects: 29
Study 26189647 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of death or severe disability
Number of subjects: 29
Study 25014766 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional blood pressure measurement
Number of subjects: 170
Study 22955309 — intervention group
Group type: COMPARATOR
Intervention: End-to-end repair
Number of subjects: 0
Study 22955309 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping repair
Number of subjects: 0
Study 20594464 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 303
Study 18358883 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 80
Study 18358883 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80
Study 16094219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate‐impregnated sponge dressing (Biopatch) covered by a transparent polyurethane dressing
Number of subjects: 145
Study 16094219 — intervention group
Group type: COMPARATOR
Intervention: Transparent polyurethane insertion site dressing (control group)
Number of subjects: 145
Study 11818701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (up to 20 mg/day)
Number of subjects: 32
Study 11818701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (up to 90 mg/day)
Number of subjects: 32
Study 10369095 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere lesions in females
Number of subjects: 0
Study 10369095 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere lesions in females
Number of subjects: 0
Study 10369095 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere lesions in males
Number of subjects: 0
Study 10369095 — intervention group
Group type: COMPARATOR
Intervention: Left hemisphere lesions in males
Number of subjects: 0
Study 10369095 — intervention group
Group type: COMPARATOR
Intervention: Control group (males)
Number of subjects: 0
Study 7474192 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2189997 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental paradigm for studying illness cognition and behavior
Number of subjects: 0
Study 7007668 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (14 students)
Number of subjects: 45
Study 7007668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (19 students)
Number of subjects: 45
Study 7007668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 students)
Number of subjects: 45
Study 31820309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 5-year incidence of T2D
Number of subjects: 32766
Study 31594555 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBER care bundle
Number of subjects: 65
Study 29126212 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day for 9 weeks
Number of subjects: 34
Study 29126212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 26496098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L Lactated Ringer's (LR)
Number of subjects: 157
Study 26496098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L Normal Saline (NS)
Number of subjects: 157
Study 26496098 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluid (noIVF)
Number of subjects: 157
Study 24045789 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-evening snack (LES) containing 200 kcal (50 g CHO)
Number of subjects: 70
Study 21320319 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid group (n = 100)
Number of subjects: 170
Study 21320319 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 70)
Number of subjects: 170
Study 19050053 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP + 10 mg sulfonylurea (SU, glipizide)
Number of subjects: 12
Study 19050053 — intervention group
Group type: COMPARATOR
Intervention: GIP
Number of subjects: 12
Study 16702497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel, 0.1%
Number of subjects: 253
Study 16702497 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 253
Study 14570790 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 32
Study 14570790 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube (LT)
Number of subjects: 32
Study 10776690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 3 mg/kg per day
Number of subjects: 103
Study 10776690 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 0.15 mg/kg per week
Number of subjects: 103
Study 8624184 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based reinforcement for cocaine-free urine samples (3 times per week for 12 weeks)
Number of subjects: 37
Study 8624184 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent vouchers
Number of subjects: 37
Study 8624184 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based reinforcement for cocaine-free urine samples
Number of subjects: 37
Study 1300623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and/or drug intervention
Number of subjects: 675
Study 6542243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platinum at 8 mg/m2 with 4 l of i.v. hydration
Number of subjects: 21
Study 6542243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platinum at 6 mg/m2 without i.v. hydration
Number of subjects: 21
Study 30243958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress task (Trier Social Stress Test)
Number of subjects: 80
Study 30243958 — intervention group
Group type: COMPARATOR
Intervention: No-stress task
Number of subjects: 80
Study 28659171 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic evacuation
Number of subjects: 1350
Study 28659171 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 1350
Study 28659171 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy
Number of subjects: 1350
Study 25936338 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 TMPnano
Number of subjects: 12
Study 25936338 — intervention group
Group type: COMPARATOR
Intervention: 1100
Number of subjects: 12
Study 25936338 — intervention group
Group type: COMPARATOR
Intervention: 1100 TMP
Number of subjects: 12
Study 23541975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT)
Number of subjects: 3560
Study 23541975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuisance bleeding at 1 month
Number of subjects: 3560
Study 21832181 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement observation of congruent movement stimuli
Number of subjects: 0
Study 21832181 — intervention group
Group type: COMPARATOR
Intervention: Movement observation of incongruent movement type
Number of subjects: 0
Study 21832181 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli not showing biological motion
Number of subjects: 0
Study 19488984 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of levosulpiride tablet
Number of subjects: 24
Study 17096435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sip volumes
Number of subjects: 505
Study 17096435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sip volumes <=2.0 mL
Number of subjects: 505
Study 15197790 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA)
Number of subjects: 0
Study 15197790 — intervention group
Group type: EXPERIMENTAL
Intervention: combretastatin A4 disodium phosphate (CA4DP)
Number of subjects: 0
Study 15197790 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD6126
Number of subjects: 0
Study 15197790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vascular-targeting agents with irradiation and other chemotherapeutic agents
Number of subjects: 0
Study 11708702 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training program
Number of subjects: 25
Study 11708702 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional weight-training program
Number of subjects: 25
Study 11708702 — intervention group
Group type: COMPARATOR
Intervention: Control (untrained) group
Number of subjects: 25
Study 9462904 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0
Study 9462904 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 0
Study 9462904 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) with adequate lung inflation
Number of subjects: 0
Study 8778745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine treatment (10 mg t.i.d. for 5 days)
Number of subjects: 0
Study 2515939 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.03 mg daily
Number of subjects: 250
Study 2515939 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal contraceptives
Number of subjects: 250
Study 1104284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable isosorbide dinitrate
Number of subjects: 16
Study 1104284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31543357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Voice Quality Index (AVQI)
Number of subjects: 90
Study 31509451 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 150
Study 31509451 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment (usual care)
Number of subjects: 150
Study 31266035 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 80
Study 31266035 — intervention group
Group type: COMPARATOR
Intervention: Early Cord Clamping (ECC)
Number of subjects: 80
Study 28787742 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine/Fluticasone (AzeFlu)
Number of subjects: 30
Study 28787742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26265231 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function monitoring with drug adjustment in patients with poor response to antiplatelet therapy
Number of subjects: 1394
Study 26265231 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy without monitoring and drug adjustment
Number of subjects: 1394
Study 26265231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification of antiplatelet treatment based on platelet function
Number of subjects: 1394
Study 26265231 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genetic testing
Number of subjects: 1394
Study 23329559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast movement training
Number of subjects: 1
Study 23329559 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow movement training
Number of subjects: 1
Study 21255776 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy and urine specimens
Number of subjects: 53
Study 19483514 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine (11PCV)
Number of subjects: 12191
Study 19483514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12191
Study 16512940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate as fortificant in bread
Number of subjects: 160
Study 16512940 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic Fe as fortificant in bread
Number of subjects: 160
Study 16512940 — intervention group
Group type: COMPARATOR
Intervention: Standard unfortified bread
Number of subjects: 160
Study 12766599 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET
Number of subjects: 16
Study 12766599 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐ECD SPECT
Number of subjects: 16
Study 12766599 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 16
Study 10333376 — intervention group
Group type: EXPERIMENTAL
Intervention: CI‐988 (100 mg)
Number of subjects: 16
Study 10333376 — intervention group
Group type: COMPARATOR
Intervention: Placebo CI‐988
Number of subjects: 16
Study 10333376 — intervention group
Group type: EXPERIMENTAL
Intervention: CI‐988 (25 mg)
Number of subjects: 16
Study 7860338 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits from the nurse
Number of subjects: 60
Study 7860338 — intervention group
Group type: COMPARATOR
Intervention: No home visits
Number of subjects: 60
Study 7860338 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A clients and families
Number of subjects: 60
Study 1933997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 241
Study 1933997 — intervention group
Group type: COMPARATOR
Intervention: Comparison drug (Doxycycline or Amoxicillin-clavulanate)
Number of subjects: 241
Study 6214989 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (1,000 mg intramuscular injection)
Number of subjects: 0
Study 6214989 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (1 g intravenous infusion)
Number of subjects: 0
Study 6214989 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (0.5 g intravenous infusion)
Number of subjects: 0
Study 6214989 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (0.5 g)
Number of subjects: 0
Study 6330478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg q.i.d. as i.v. bolus followed by 150 mg orally twice daily
Number of subjects: 380
Study 6330478 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg q.i.d. intravenously and 1,000 mg daily orally in divided doses
Number of subjects: 380
Study 6330478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 380
Study 6330478 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 380
Study 29625605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 50
Study 29625605 — intervention group
Group type: COMPARATOR
Intervention: Otorhinolaryngologic surgery without involvement of the oral cavity
Number of subjects: 50
Study 27841725 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 14838
Study 27841725 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine
Number of subjects: 14838
Study 25351573 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing during TKA
Number of subjects: 50
Study 25351573 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing during TKA
Number of subjects: 50
Study 22178007 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group member (same university)
Number of subjects: 0
Study 22178007 — intervention group
Group type: COMPARATOR
Intervention: Out-group member (another tertiary institution)
Number of subjects: 0
Study 20431425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix (study vaccine)
Number of subjects: 3325
Study 20431425 — intervention group
Group type: COMPARATOR
Intervention: Fluzone (control vaccine)
Number of subjects: 3325
Study 20431425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 3325
Study 17507739 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (1 g CHO/kg)
Number of subjects: 11
Study 17507739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16213293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 123
Study 16213293 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (Neoral)
Number of subjects: 123
Study 12455359 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-91 protocol
Number of subjects: 687
Study 12455359 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Number of subjects: 687
Study 10331734 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily oral rifapentine doses of 150, 300, or 600 mg given on day 1 and again on days 4-10
Number of subjects: 23
Study 10331734 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 600 mg dose given on days 1, 4, 7, and 10
Number of subjects: 23
Study 7558928 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage-colony-stimulating factor (rhGM-CSF)
Number of subjects: 0
Study 7558928 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 1683337 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (average daily dose of 168 +/- 15 mg)
Number of subjects: 20
Study 1683337 — intervention group
Group type: COMPARATOR
Intervention: Zotepine (average daily dose of 241 +/- 70 mg)
Number of subjects: 20
Study 1683337 — intervention group
Group type: COMPARATOR
Intervention: Perazine (average daily dose of 348 +/- 09 mg)
Number of subjects: 20
Study 7325348 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine during and after the operation
Number of subjects: 22
Study 7325348 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural opiate analgesia
Number of subjects: 22
Study 7325348 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg of morphine
Number of subjects: 22
Study 31464773 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (a highly purified omega-3 fatty acid, eicosapentaenoic acid ethyl ester)
Number of subjects: 0
Study 31464773 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Number of subjects: 0
Study 29718095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based chemoradiotherapy (CRT) with oxaliplatin
Number of subjects: 1191
Study 29718095 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil-only CRT
Number of subjects: 1191
Study 29718095 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR score (low)
Number of subjects: 1191
Study 29718095 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR score (intermediate)
Number of subjects: 1191
Study 29718095 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR score (high)
Number of subjects: 1191
Study 29718095 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR score (low vs high)
Number of subjects: 1191
Study 29718095 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR score (low vs intermediate)
Number of subjects: 1191
Study 27211290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (n = 30)
Number of subjects: 60
Study 27211290 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 29)
Number of subjects: 60
Study 27211290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 24047571 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular control (NMC) programme
Number of subjects: 40
Study 24047571 — intervention group
Group type: COMPARATOR
Intervention: Control programme
Number of subjects: 40
Study 22912941 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 48
Study 22912941 — intervention group
Group type: COMPARATOR
Intervention: Control group (participative involvement)
Number of subjects: 48
Study 20482495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena IUS
Number of subjects: 103
Study 20482495 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 103
Study 16955065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sforzesco brace (SPoRT)
Number of subjects: 30
Study 16955065 — intervention group
Group type: COMPARATOR
Intervention: Lyon brace (LY)
Number of subjects: 30
Study 15573395 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg IFN-gamma1b
Number of subjects: 66
Study 15573395 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 microg IFN-gamma1b
Number of subjects: 66
Study 15573395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 12368643 — intervention group
Group type: COMPARATOR
Intervention: Radiographs alone
Number of subjects: 3
Study 12368643 — intervention group
Group type: COMPARATOR
Intervention: Radiographs with CT scan
Number of subjects: 3
Study 12368643 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographs with MRI
Number of subjects: 3